Mark R. Tanner
YOU?
Author Swipe
View article: CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide
CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide Open
Introduction. Allogeneic hematopoietic stem cell transplant (SCT) is an effective treatment for hematologic malignancies. The engrafted cells provide hematopoietic recovery and immune reconstitution and mediate the graft-vs-malignancy effe…
View article: Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel Open
Increasing evidence suggests that the gut microbiome may influence the responses and toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapy. We conducted whole-genome shotgun sequencing on stool samples (N = 117) colle…
View article: Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation Open
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34 + cell dose remains unclear. We conducted a retrospective study on MM patients undergoing upfront transplant between 2005…
View article: Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation Open
View article: Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation Open
Summary The second revision of the International Staging System (R2‐ISS) is a simple tool to risk‐stratify newly diagnosed multiple myeloma (NDMM) patients. Here, we completed a retrospective analysis to evaluate the utility of R2‐ISS in N…
View article: Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience Open
The prognostic impact of additional copies of chromosome 1q (1q + ) on outcomes of newly-diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation (autoSCT) is unclear. We conducted a retrospective single-center anal…
View article: Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation Open
Background The prognostic significance of minimal residual disease (MRD) status before autologous hematopoietic stem cell transplantation (autoHCT) in patients with multiple myeloma (MM) has not been clearly elucidated. Methods Retrospecti…
View article: Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma Open
View article: P1279: OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES
P1279: OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES Open
Topic: 22. Stem cell transplantation - Clinical Background: Patients with multiple myeloma (MM) and high-risk (HR) cytogenetic abnormalities have inferior outcomes, and are under-represented in clinical trials. There is paucity of data reg…
View article: P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION Open
Topic: 22. Stem cell transplantation - Clinical Background: Maintenance therapy is considered standard of care after upfront autologous hematopoietic stem cell transplantation (auto-HCT) for patients with newly diagnosed multiple myeloma (…
View article: P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT Open
Topic: 22. Stem cell transplantation - Clinical Background: There is growing recognition that young adults with cancer have unique biological characteristics, clinical features, and treatment outcomes. Multiple myeloma (MM) is primarily a …
View article: Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience
Single‐agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience Open
The optimal duration of lenalidomide (Len) maintenance for patients with multiple myeloma (MM) after autologous stem cell transplantation (autoHCT) is unknown. We conducted a retrospective single‐center analysis of adult MM patients that r…
View article: Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant Open
Summary Multiple myeloma (MM) primarily affects older patients. There are scarce data on the outcomes of young adults undergoing autologous transplantation (auto‐HCT). In this single‐centre analysis, we included 117 younger patients, with …
View article: Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients Open
Most patients with multiple myeloma (MM) undergoing autologous hematopoietic stem cell transplantation (autoHCT) eventually relapse, perhaps due to the presence of clonal plasma cells (CPC) in the autograft. We conducted a retrospective an…
View article: Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver
Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver Open
Targeting the Kv1.3 potassium channel has proven effective in reducing obesity and the severity of animal models of autoimmune disease. Stichodactyla toxin (ShK), isolated from the sea anemone Stichodactyla helianthus , is a potent blocker…
View article: Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma Open
Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
View article: Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma Open
To explore the role of clonal hematopoiesis (CH) in chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep sequencing on buffy coats collected during the 21 days before lymphodepleting chemotherapy from 114 lar…
View article: Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma Open
To explore the role of clonal hematopoiesis (CH) in chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep sequencing on buffy coats collected during the 21 days before lymphodepleting chemotherapy from 114 lar…
View article: Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma Open
Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
View article: Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant
Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant Open
Multiple myeloma (MM) is a common haematological malignancy, accounting for 1.8% of all new cases of cancer in the United States.1 The prevalence of MM is slightly higher in men compared to women, 8.8 versus 5.7 new cases per 100 000 perso…
View article: Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience Open
View article: Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia Open
The current global platelet supply is often insufficient to meet all the transfusion needs of patients, in particular for those with alloimmune thrombocytopenia. To address this issue, we have developed a strategy employing a combination o…
View article: Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma Open
View article: Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma Open
To explore the role of clonal hematopoiesis (CH) in chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep sequencing on buffy coats collected during the 21 days before lymphodepleting chemotherapy from 114 lar…
View article: Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy
Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy Open
To explore the role of clonal hematopoiesis (CH) on chimeric antigen receptor (CAR) T-cell therapy outcomes, we performed targeted deep-sequencing on 114 large B-cell lymphoma patients treated with anti-CD19 CAR T-cells. We detected CH in …
View article: Antioxidant Carbon Nanoparticles Inhibit Fibroblast-Like Synoviocyte Invasiveness and Reduce Disease Severity in a Rat Model of Rheumatoid Arthritis
Antioxidant Carbon Nanoparticles Inhibit Fibroblast-Like Synoviocyte Invasiveness and Reduce Disease Severity in a Rat Model of Rheumatoid Arthritis Open
Reactive oxygen species have been involved in the pathogenesis of rheumatoid arthritis (RA). Our goal was to determine the effects of selectively scavenging superoxide (O2•−) and hydroxyl radicals with antioxidant nanoparticles, called pol…
View article: Modulation of Lymphocyte Potassium Channel K<sub>V</sub>1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin
Modulation of Lymphocyte Potassium Channel K<sub>V</sub>1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin Open
We describe a cysteine-rich, membrane-penetrating, joint-targeting, and remarkably stable peptide, EgK5, that modulates voltage-gated KV1.3 potassium channels in T lymphocytes by a distinctive mechanism. EgK5 enters plasma membr…
View article: AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9
AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9 Open
View article: KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis
KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis Open
View article: Structure of Lymphocyte Potassium Channel K <sub>v</sub>1.3 and Modulation by Cell-Penetrating Immunomodulatory Plant Defensin
Structure of Lymphocyte Potassium Channel K <sub>v</sub>1.3 and Modulation by Cell-Penetrating Immunomodulatory Plant Defensin Open